Capricorn Investment Group Takes 1.7M Share Stake in HeartFlow (HTFL)

The acquisition of 1.7 million shares by Capricorn Investment Group marks a watershed moment for HeartFlow (NASDAQ: HTFL), signaling a robust institutional endorsement of the company’s AI-driven cardiac diagnostic platform. Capricorn, an investment firm founded by eBay’s first president Jeff Skoll, is renowned for its focus on impact investing and long-term value creation. By taking a significant stake in HeartFlow, Capricorn is betting on the company’s ability to fundamentally shift the standard of care in cardiology from invasive diagnostic procedures to non-invasive, AI-augmented analysis.

HeartFlow’s primary offering is its FFR-CT (Fractional Flow Reserve derived from Computed Tomography) technology. This system uses deep learning and highly complex fluid dynamics algorithms to create a personalized 3D model of a patient’s coronary arteries. By analyzing blood flow and pressure drops across stenoses (narrowings), HeartFlow provides clinicians with data that previously required an invasive cardiac catheterization. The clinical utility of this technology has been validated in numerous trials, showing it can reduce unnecessary invasive procedures by over 60% while improving diagnostic accuracy.

“

The company expects to generate between $218 million and $222 million in annual revenue, a target that suggests a steepening growth curve as its technology gains wider adoption in hospital systems globally.

The timing of Capricorn’s investment is particularly noteworthy, coming just days after HeartFlow issued aggressive revenue guidance for 2026. The company expects to generate between $218 million and $222 million in annual revenue, a target that suggests a steepening growth curve as its technology gains wider adoption in hospital systems globally. This growth is being fueled by the acceleration of the PCI Navigator, a tool designed to assist interventional cardiologists in planning stenting procedures with greater precision. By simulating the impact of a stent before the procedure even begins, the PCI Navigator represents a move from pure diagnosis into procedural planning, significantly expanding HeartFlow’s addressable market.

Furthermore, HeartFlow is expanding its capabilities in plaque analysis. While FFR-CT focuses on blood flow, the company’s newer plaque modules allow for the characterization of the types of plaque present in the vessel walls—specifically identifying vulnerable plaque that is most likely to cause a heart attack. This dual approach—combining functional flow data with anatomical plaque data—positions HeartFlow as a comprehensive one-stop shop for cardiac CT analysis, a space where it competes with emerging players like Cleerly and established imaging giants.